Friday, March 4, 2016, 87 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $21.30 to $2,750,000.00.

Highlighted Stocks Traded by Insiders:

Marsh & McLennan Companies (MMC) - FREE Research Report

Beshar Peter J, who is EVP and General Counsel at Marsh & McLennan Companies, sold 18,309 shares at $57.52 on March 4, 2016. Following this transaction, the EVP and General Counsel owned 135,953 shares meaning that the stake was reduced by 11.87% with the 18,309-share transaction.

The shares most recently traded at $57.89, up $0.37, or 0.64% since the insider transaction. Historical insider transactions for Marsh & McLennan Companies go as follows:

  • 4-Week # shares bought: 3,000
  • 4-Week # shares sold: 25,509
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 25,509
  • 24-Week # shares bought: 3,000
  • 24-Week # shares sold: 25,509

The average volume for Marsh & McLennan Companies has been 2.5 million shares per day over the past 30 days. Marsh & McLennan Companies has a market cap of $30.1 billion and is part of the financial sector and insurance industry. Shares are up 4.62% year-to-date as of the close of trading on Friday.

Marsh & McLennan Companies, Inc., a professional services firm, provides advice and solutions in the areas of risk, strategy, and people worldwide. It operates through two segments, Risk and Insurance Services; and Consulting. The stock currently has a dividend yield of 2.15%. The company has a P/E ratio of 19.4. Currently, there are 9 analysts who rate Marsh & McLennan Companies a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MMC - FREE

TheStreet Quant Ratings

rates Marsh & McLennan Companies as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, notable return on equity and solid stock price performance. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Marsh & McLennan Companies Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alexion Pharmaceuticals (ALXN) - FREE Research Report

O'Neill Julie, who is EVP. Global Operations at Alexion Pharmaceuticals, sold 651 shares at $149.55 on March 4, 2016. Following this transaction, the EVP. Global Operations owned 36,034 shares meaning that the stake was reduced by 1.77% with the 651-share transaction.

The shares most recently traded at $149.50, down $0.05, or 0.03% since the insider transaction. Historical insider transactions for Alexion Pharmaceuticals go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 5,087
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 8,154
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 87,370

The average volume for Alexion Pharmaceuticals has been 1.8 million shares per day over the past 30 days. Alexion Pharmaceuticals has a market cap of $32.9 billion and is part of the health care sector and drugs industry. Shares are down 24.27% year-to-date as of the close of trading on Friday.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company has a P/E ratio of 217.7. Currently, there are 15 analysts who rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALXN - FREE

TheStreet Quant Ratings

rates Alexion Pharmaceuticals as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full

Alexion Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Encore Capital Group (ECPG) - FREE Research Report

Sorensen Norman R, who is Director at Encore Capital Group, bought 2,000 shares at $26.58 on March 4, 2016. Following this transaction, the Director owned 13,058 shares meaning that the stake was boosted by 18.09% with the 2,000-share transaction.

The shares most recently traded at $27.68, up $1.10, or 3.97% since the insider transaction. Historical insider transactions for Encore Capital Group go as follows:

  • 4-Week # shares bought: 26,300
  • 4-Week # shares sold: 16,000
  • 12-Week # shares bought: 29,300
  • 12-Week # shares sold: 16,000
  • 24-Week # shares bought: 29,300
  • 24-Week # shares sold: 16,000

The average volume for Encore Capital Group has been 435,500 shares per day over the past 30 days. Encore Capital Group has a market cap of $658.0 million and is part of the financial sector and financial services industry. Shares are down 7.22% year-to-date as of the close of trading on Friday.

Encore Capital Group, Inc., a specialty finance company, together with its subsidiaries, provides debt recovery solutions for consumers and property owners across a range of financial assets worldwide. The company operates in two segments, Portfolio Purchasing and Recovery, and Tax Liens. The company has a P/E ratio of 15.4. Currently, there are 5 analysts who rate Encore Capital Group a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ECPG - FREE

TheStreet Quant Ratings

rates Encore Capital Group as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and generally higher debt management risk. Get the full

Encore Capital Group Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.